Nektar Therapeutics (NKTR) announced Wednesday that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. (CBMG).The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15) receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy.Preclinical and early clinical data suggest that IL-15 can improve proliferation and persistence of cellular therapies including TIL, TCR, and CAR-T therapies to increase specific anti-tumor activity.Under the new collaboration, CBMG will add NKTR-255 to its ongoing CBMG-sponsored Phase 1 clinical trial evaluating C-TIL051 in NSCLC patients who have relapsed on or were refractory to anti-PD-1 therapy..

Nektar Therapeutics（NKTR）周三宣布已与Cellular Biomedicine Group Inc.（CBMG）进行新的临床研究合作。该研究将评估Nektar的NKTR-255，一种新型白细胞介素-15（IL-15）受体激动剂，结合CBMG的C-TIL051，一种肿瘤浸润淋巴细胞（TIL）疗法，在抗PD-1治疗复发或难治的晚期非小细胞肺癌（NSCLC）患者中。临床前和早期临床数据表明，IL-15可以改善细胞疗法（包括TIL，TCR和CAR-T疗法）的增殖和持久性，以增加特异性抗肿瘤活性。在新的合作下，CBMG将在其正在进行的CBMG赞助的1期临床试验中添加NKTR-255，该试验评估了抗PD-1治疗复发或难治的NSCLC患者的C-TIL051。。

The study is expected to enroll a total of 20 patients. Nektar will contribute NKTR-255 supply for the study. Nektar and CBMG will each maintain existing global rights to their respective investigational medicines.For More Such Health News, visit rttnews.com For comments and feedback contact: editorial@rttnews.comBusiness News.

该研究预计共招募20名患者。Nektar将为研究提供NKTR-255供应。Nektar和CBMG将各自保留其各自研究药物的现有全球权利。有关更多此类健康新闻，请访问rttnews.com获取评论和反馈联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In June 2023

2023年6月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In April 2023

2023年4月面临FDA决定的生物技术股票